Keros Therapeutics Conference Call Summary Company Overview - **Company**: Keros Therapeutics (NasdaqGM: KROS) - **Event**: 2026 Conference at the Leerink Partners Global Healthcare Conference - **Speaker**: CEO Jas Sira Key Highlights from 2025 - **Takeda Partnership**: The partnership with Takeda was established at the end of 2024, transitioning the elritercept program to Takeda, which is now responsible for its development. Keros will continue to advise on the program [4] - **Clinical Trials**: Takeda is advancing elritercept into Phase III trials for myelofibrosis, with decisions expected later in the year [4] - **Cibotercept Program**: The program was deprioritized due to safety signals, leading to a halt in dosing [5] - **Rinvatercept Development**: Keros plans to advance rinvatercept into neuromuscular indications, specifically targeting Duchenne Muscular Dystrophy (DMD) and Amyotrophic Lateral Sclerosis (ALS) [5][6] Pipeline and Platform - **TGF-beta Superfamily Focus**: Keros continues to focus on the TGF-beta pathway, utilizing ligand traps based on activin receptors for various indications [9][10] - **Rinvatercept Mechanism**: Rinvatercept inhibits activin A and myostatin, promoting muscle regeneration by counteracting negative regulators of skeletal muscle [12][13] Clinical Data and Efficacy - **Duchenne Muscular Dystrophy (DMD)**: - Rinvatercept showed promising results in healthy volunteers, including increases in lean mass and improvements in bone mineral density [19] - The drug aims to reduce fat mass, particularly unhealthy abdominal fat, which is significant for DMD patients who may develop metabolic syndrome [19] - **Phase 2 Study Design**: The study will include late ambulatory and non-ambulatory cohorts to evaluate safety and efficacy signals [22][23] ALS Development - **Mechanism in ALS**: The focus is on preserving muscle function despite the loss of neuromuscular junctions, with preclinical data showing treated animals maintaining better weight and grip strength compared to untreated ones [38][39] - **Regulatory Engagement**: Keros plans to engage with the FDA regarding trial design and patient population targeting slow-progressing ALS cases [43] Elritercept and Takeda Partnership - **Phase 2 Results**: Elritercept demonstrated a 50% response rate in treating anemia in MDS patients, differentiating itself from luspatercept by binding to activin A [52] - **Revenue Potential**: The partnership includes a $200 million upfront payment and up to $1.1 billion in milestone payments, with royalties starting in low double digits [60][61] Future Outlook - **Pipeline Expansion**: Keros anticipates advancing additional assets into the clinic by the first half of 2028, with ongoing updates expected throughout the year [62] Conclusion - Keros Therapeutics is positioned for significant advancements in its clinical programs, particularly in DMD and ALS, while leveraging its partnership with Takeda to enhance its market presence in anemia treatments. The focus on innovative mechanisms and robust clinical data supports a positive outlook for the company's future endeavors.